步长制药(603858) - 2017 Q1 - 季度财报

Financial Performance - Operating revenue increased by 21.33% to CNY 2,428,574,126.42 year-on-year[6] - Net profit attributable to shareholders rose by 15.30% to CNY 222,382,462.71 compared to the same period last year[6] - The diluted earnings per share increased by 3.52% to CNY 0.3262 compared to the previous year[6] - Net profit for Q1 2017 reached CNY 220,581,563.46, representing a 14.6% increase from CNY 192,438,899.07 in Q1 2016[26] - The company reported a gross profit margin of approximately 10.9% for Q1 2017, compared to 9.1% in Q1 2016[26] Cash Flow and Liquidity - Net cash flow from operating activities surged by 417.08% to CNY 460,538,233.54 year-to-date[6] - Cash received from operating activities fell by 36.89% to RMB 44,214,486.37, reflecting a decrease in government grants[16] - The company's cash and cash equivalents decreased to CNY 1,010,249,809.60 from CNY 2,149,254,379.06 year-over-year[23] - The total cash and cash equivalents at the end of Q1 2017 were ¥1,822,149,809.60, a significant rise from ¥155,364,889.44 at the end of Q1 2016[35] - The net cash flow from operating activities for Q1 2017 was approximately ¥460.54 million, a significant increase from ¥89.06 million in Q1 2016[32] Assets and Liabilities - Total assets decreased by 8.29% to CNY 17,126,229,434.31 compared to the end of the previous year[6] - Total liabilities as of March 31, 2017, were CNY 3,833,973,460.57, down from CNY 4,536,172,656.39 at the end of the previous year[24] - The company's total equity as of March 31, 2017, was CNY 6,856,802,542.98, a slight decrease from CNY 6,892,231,675.53[24] - Total cash inflow from investment activities reached ¥1,327,344,884.18, compared to ¥605,269,955.99 in Q1 2016, marking an increase of about 119%[34] Operating Costs and Expenses - Operating costs increased by 31.27% year-on-year, amounting to RMB 451,243,487.99 in Q1 2017, primarily due to revenue growth and rising production costs[15] - Management expenses rose by 32.80% year-on-year to RMB 227,614,624.16, mainly driven by increased employee compensation and R&D expenses[15] - The company reported a 38.53% increase in income tax expenses, totaling RMB 66,921,592.63, due to a decrease in recognized deferred tax assets[15] Financing Activities - Short-term borrowings increased dramatically to CNY 1,650,000,000.00 from CNY 6,000,000.00, reflecting a substantial rise in financing activities[13] - The company raised approximately ¥1.65 billion through financing activities in Q1 2017, compared to ¥350 million in the same period last year, marking a significant increase[33] - Cash inflow from financing activities amounted to ¥1,350,000,000.00, up from ¥720,000,000.00 in the previous year, indicating an increase of approximately 88%[35] Shareholder Information - The number of shareholders reached 63,070 by the end of the reporting period[9] - The company received government subsidies amounting to CNY 25,103,232.61, which are closely related to its normal business operations[8]